शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ALBERTDAVDNSEAlbert David Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 11 Feb, 2026 · 16:47 IST

Albert David Q3 FY26 profit at Rs 15.3 cr, revenue up 8% YoY

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.2%Reaction day
₹712.00
prior close
₹765.05
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+4.7% vs market
Pharmaceuticals peers, median of 157sector-0.7%+4.9% vs sector

On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.6
10m
-0.3
15m
-0.4
30m
-1.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.2-0.5+4.7-0.7+4.9
Next day
+5.8-2.0+7.7-1.4+7.2
2d
+3.2-2.7+5.9-2.1+5.4
3d
+2.9-1.7+4.7-1.6+4.6
4d
+2.9-1.4+4.3-1.6+4.5
5d
+0.3-2.8+3.1-2.5+2.8
1w
+1.0-2.8+3.8-2.9+3.9
15d
-4.8-8.4+3.6-6.5+1.7
1m
-4.4-9.1+4.7-6.6+2.3
2m
+0.6-4.0+4.7-3.5+4.1
3m
+11.0+2.6+8.3+0.7+10.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Albert David reported Q3 FY26 standalone profit of Rs 15.30 crore versus a loss of Rs 9.39 crore in Q3 FY25. Revenue from operations grew 8.2 percent YoY to Rs 89.93 crore. For nine months, revenue fell 8.5 percent to Rs 247.73 crore while PAT dropped 27.6 percent to Rs 19.94 crore. Other income swung from negative Rs 9.01 crore in Q3 FY25 to positive Rs 12.40 crore in Q3 FY26, aiding the profit turnaround. Auditors issued an unmodified review.

Likely market impact

Q3 profit turnaround driven by other income swing, but 9-month revenue and PAT remain below last year. Watch for sustained revenue recovery.